Published: 10 February 2007
The decades-long war between brand-name and generic drug manufacturers shows no signs of abating. But with a rapidly aging population and the spectre of new diseases on the horizon, there's new pressure to find a solution soon that can both motivate innovative research and sustain affordable drug prices. McGill's Richard Gold, director of the Centre for Intellectual Property Policy and a professor in IP and common-law property, is interviewed for this story in the Canadian Bar Association's National Magazine.